| 翻訳と辞書 |
XEN-D0101
XEN-D0101 is a drug that was developed to treat atrial fibrillation. Xention, a biopharmaceutical company based in Cambridge, United Kingdom, created XEN-D0101 along with other ion channel-modulating drugs.〔Xention – Creating new medicines. (n.d.). Xention – Creating new medicines. Retrieved March 1, 2013, from http://www.xention.com〕 XEN-D0101 is a selective antagonist of the voltage-gated potassium channel Kv1.5.〔Ford, John, Milnes, James, Wettwer, Erich, Christ, Torsten, Rogers, Marc ; Sutton, Kathy, Madge, David, Virag, Laszlo Jost, Norbert, Horvath, Zoltan ; Matschke, Klaus ; Varro, Andras ; Ravens, Ursula Human. (2013) Electrophysiological and Pharmacological Properties of XEN-D0101: A Novel Atrial Selective Kv1.5/IKur Inhibitor. Journal of Cardiovascular Pharmacology〕 Atrial fibrillation is the main focus of Xention’s drug development, as it is the most common cardiac arrhythmia (irregular heart beat) seen in patients.〔Tamargo, J., Caballero, R., Gomez, R., & Delpon, E. (2009). I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillation. Expert Opin Investigating Drugs, 18, 399-416.〕
==Atrial fibrillation==
Atrial Fibrillation (AF) is an arrhythmia that occurs in 1-2% of the general population.〔Milnes, J., Louis, L., Madge, D., & Ford, J. (2008). The Atrial Antiarrhythmic Drug XEN-D0101 Selectively Inhibits the Human Ultra-Rapid Delayed-Rectifier Potassium Current (IKur) Over Other Cardiac Ion Channels. Circulation, 118, 342-357.〕 AF is linked to several cardiac causes including hypertension and coronary artery disease, and AF increases the risk for stroke.〔Milnes, J., Louis, L., Madge, D., & Ford, J. (2008). The Atrial Antiarrhythmic Drug XEN-D0101 Selectively Inhibits the Human Ultra-Rapid Delayed-Rectifier Potassium Current (IKur) Over Other Cardiac Ion Channels. Circulation, 118, 342-357.〕 Current strategies to manage AF are effective but many are associated with adverse side effects.〔Ford, John, Milnes, James, Wettwer, Erich, Christ, Torsten, Rogers, Marc ; Sutton, Kathy, Madge, David, Virag, Laszlo Jost, Norbert, Horvath, Zoltan ; Matschke, Klaus ; Varro, Andras ; Ravens, Ursula Human. (2013) Electrophysiological and Pharmacological Properties of XEN-D0101: A Novel Atrial Selective Kv1.5/IKur Inhibitor. Journal of Cardiovascular Pharmacology〕 Due to the irregular rhythm occurring in the atria, targeting them with antiarrhythmic drugs without affecting the ventricles would provide a desirable outcome.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「XEN-D0101」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|